A K-beauty launch in the United States does not end when a product clears customs and reaches a retailer. Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), the company whose name appears on a cosmetic label may become the “responsible person” with mandatory duties when it receives a serious adverse-event report. The deadline can begin before a Korean headquarters team has completed an investigation, so unclear ownership, untranslated records, or customer-service delays create real compliance risk. This guide explains who is responsible, which outcomes meet FDA’s serious-event definition, how the 15-business-day reporting timeline works, what label and follow-up information must accompany a report, and how Korean brands and U.S. partners can build a documented intake process. It provides general operational information, not legal or medical advice.
Why Adverse-Event Readiness Matters
MoCRA significantly expanded FDA’s authority over cosmetics. One of its direct postmarket requirements is mandatory reporting of serious adverse events associated with cosmetic products used in the United States. FDA states on its MoCRA overview that a responsible person must submit a report within 15 business days and include a copy of the label on or within the retail packaging.
This obligation is different from ordinary customer service. A refund, replacement, or apology does not complete federal reporting duties. Conversely, not every complaint is a serious adverse event requiring mandatory submission. A company needs a consistent method for capturing all complaints, escalating potential serious cases, and preserving the facts supporting its classification.
For a Korean brand working through a U.S. distributor, the risk often lies between organizations. A shopper may contact a marketplace seller, a retailer may notify the importer, and the Korean manufacturer may hold the lot records. Contracts and procedures should move information promptly to the label’s responsible person without assuming another party will report.
Identify the Responsible Person
FDA defines the responsible person as the manufacturer, packer, or distributor whose name appears on the cosmetic product label under the applicable law. It is a label-based role, not simply the factory, importer of record, trademark owner, or company that receives the first email.
Before launch, review the exact U.S. retail label for every SKU and identify the named entity. Map its legal name, address, complaint contact, regulatory lead, backup decision-maker, and FDA submission account. If the Korean manufacturer, U.S. subsidiary, importer, and distributor use different names, document which entity is the responsible person for each label version.
The label must also provide domestic contact information through which the responsible person can receive adverse-event reports. A practical system routes phone, web, email, retailer, social-media, and marketplace complaints into one controlled queue. Staff should never delete or ignore a complaint because it arrived through an informal channel.
Small-business exemptions should not be casually assumed to eliminate adverse-event duties. FDA’s MoCRA page describes exemptions for certain requirements, but serious-event reporting remains a core responsibility. Obtain qualified advice about the exact business and product rather than copying another brand’s conclusion.
Recognize a Serious Adverse Event
Covered Outcomes
FDA’s current cosmetic complaint and reporting page defines a serious adverse event as one resulting in death, a life-threatening experience, inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, infection, or significant disfigurement. Significant disfigurement includes serious and persistent rashes, second- or third-degree burns, significant hair loss, or persistent or significant alteration of appearance beyond what is intended under customary use.
An event can also be serious when reasonable medical judgment indicates that medical or surgical intervention was required to prevent one of those outcomes. This means classification cannot rely only on whether the customer used the word “serious” or whether the company agrees that the product caused the reaction.
The legal obligation concerns an event associated with use; the company should not delay intake while trying to prove causation. Capture the reporter’s account accurately and separate what was reported from the company’s later assessment.
Triage Without Practicing Medicine
Customer-service staff should use a structured questionnaire and escalate red flags, but they should not diagnose, minimize symptoms, or tell someone to continue using a suspect product. Immediate safety communication can advise stopping use and seeking urgent professional care when appropriate, while the regulatory team collects facts.
Useful questions include the affected person’s age, event description, onset and duration, medical treatment, hospitalization, outcome, product name, use instructions followed, lot number, purchase source, other products used, and permission for follow-up. Collect only information needed for the safety process and protect personal and medical data.
Manage the 15-Business-Day Deadline
FDA requires submission within 15 business days after the responsible person receives a serious adverse-event report. The company should timestamp initial awareness and not wait for a perfect investigation. A written procedure should define what counts as receipt, who starts the regulatory clock, how weekends and federal holidays are handled, and who approves the submission.
FDA also requires follow-up information. If the responsible person receives medical or other information within one year of the initial report, the new information must be submitted within 15 business days. Keep the case open for follow-up tracking even after the initial form is sent.
Build internal targets shorter than the legal deadline. For example, route potential serious cases immediately, perform initial triage within one business day, request missing information promptly, and reserve time for quality review and label attachment. These are operational examples, not FDA-prescribed sub-deadlines.
Do not hold a report solely because a consumer does not answer every question. The regulatory lead should evaluate available information and document reasonable follow-up efforts. Qualified counsel or a regulatory professional should address uncertain reportability.
Build a Complete FDA Report
FDA directs responsible persons to use mandatory MedWatch reporting pathways. Its updated Form FDA 3500A instructions identify the responsible person as the manufacturer, packer, or distributor named on the cosmetic label and explain which form sections apply to cosmetics.
The report should accurately identify the person affected, reporter, event, suspect cosmetic, dates, outcome, medical information available, and responsible person. Include a copy of the label on or within the retail package. FDA’s instructions also encourage supporting material such as label scans and images of the event when available and appropriate.
Use the product name, variant, size, lot or batch code, and purchase source exactly as documented. Preserve the label version in use at the time. A current label may differ from the one seen by the consumer, so version control is essential.
As of the official 2026 instructions, FDA describes electronic submission options and current Form 3500A procedures. The AEMS electronic-submission page explains account setup for cosmetic responsible persons using the Safety Reporting Portal. Because processes can change, confirm the current FDA page each time rather than relying on an old saved form.
- Use one controlled case number across customer service, quality, and regulatory files.
- Attach the correct U.S. retail label and preserve its version.
- Keep reporter statements distinct from company conclusions.
- Document submission date, method, confirmation, and follow-up due dates.
- Protect health and contact information with role-based access.
Records, Follow-Ups, and Inspections
MoCRA gives FDA access to adverse-event records during inspections. FDA’s 2026 draft guidance announcement on cosmetics records access discusses records such as communications with reporters, seriousness assessments, and FDA submissions. It describes six-year retention for adverse-event records, or three years for qualifying small businesses, and the need for English translations. Because this is draft guidance, companies should distinguish statutory requirements from FDA’s current recommendations and confirm the final status.
Records should allow an inspector or internal reviewer to reconstruct what happened: original complaint, date received, follow-up attempts, medical information, product and lot identity, label, seriousness decision, report, submission confirmation, investigation, corrective actions, and later updates. Do not overwrite the original report when facts change; add dated follow-up entries.
Korean-language manufacturing records may be relevant to investigation, but the U.S. responsible person needs timely access and appropriate translation. Agree in advance on translation ownership, secure transfer, time zones, and escalation contacts. Waiting until a serious event occurs is too late to design this workflow.
A Practical K-Beauty Workflow
First, create a single adverse-event intake form used by all consumer-facing channels. Second, train staff to recognize potential serious outcomes and route them immediately. Third, connect each case to master data containing the product listing, U.S. label, formula, manufacturer, lot coding, distribution dates, and responsible person.
Fourth, establish a cross-border response team with regulatory, quality, customer service, medical or safety expertise where appropriate, privacy, and legal support. Define who decides reportability and who may submit to FDA. Fifth, test the procedure with a tabletop scenario before launch and at regular intervals.
Finally, use complaint trends for quality improvement without assuming every report proves causation. Compare events by product, lot, symptom, retailer, and time period; evaluate whether investigation, supplier notification, distribution hold, corrective action, or recall assessment is warranted. FDA’s 2026 AEMS public cosmetics dashboard announcement explains that the database includes mandatory and voluntary reports, but reports alone do not establish that a product caused an event.
Risks and Limitations
This article summarizes public FDA information as of 2026 and is not legal, medical, privacy, or regulatory advice. Electronic systems, forms, guidance status, and submission instructions can change. Confirm current FDA resources and obtain qualified advice for the company’s products, facts, and contracts.
A report to FDA does not by itself prove causation, defect, or liability, and lack of a report does not prove safety. Companies must avoid retaliating against reporters, making unsupported medical judgments, or using privacy as a reason to ignore regulatory duties. Data collection should be necessary, secure, and consistent with applicable law.
Conclusion & Key Takeaways
For K-beauty brands entering the United States, serious adverse-event reporting is a label-owner responsibility that must be operational before the first sale. Identify the responsible person, capture complaints from every channel, recognize FDA’s serious outcomes, submit within 15 business days, attach the correct label, and track new information for one year.
The strongest system joins U.S. customer service with Korean quality records through documented ownership, translation, privacy controls, and rehearsed deadlines. Timely, accurate reporting is not only a compliance task; it is a foundation for learning from real-world product use and responding responsibly when consumers experience harm.
